Revon Media
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us
No Result
View All Result
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us
No Result
View All Result
Revon Media
No Result
View All Result

Managing costs pays off for Duopharma Biotech

Managing costs pays off for Duopharma Biotech
Share on FacebookShare on Twitter

Initiatives and measures to manage operational costs in 2020 have paid off for one of Malaysia’s leading pharmaceutical companies, Duopharma Biotech Bhd.

Its group net profit rose six per cent to RM58.61 million for its FY Dec 31, 2020 against RM55.27 million the previous year. For its fourth quarter ended Dec 31, 2020, its net profit rose 34.6 per cent to RM16.2 million against RM12.03 million in the same quarter the previous year.

This rise in 2020 profit comes despite a nominal drop in revenue of 1.1 per cent to RM569.9 million from RM576.46 million in 2019. For the fourth quarter 2020, revenue dipped 2.7 per cent to RM134.09 million from RM137.76 million previously.

Duopharma declared declared a second interim dividend of six sen per share amounting to RM42.36 million.

Group Managing Director Leonard Ariff Abdul Shatar said, Duopharma’s one-year extension for the supply and delivery of human insulin products to the government with an additional value of RM19.63 million will augur well for the group.

It has also received a 25-month extension for the supply of pharmaceutical and/or non-pharmaceutical products to hospitals, clinics and others under the government.

“The extensions augur well for the Duopharma Biotech Bhd Group as these stabilise a significant portion of group revenue. With this assurance, it places us in a better position to mobilise our resources to intensify our foray into specialty and niche products,” he said.

Duopharma Biotech also recently entered into a term sheet agreement with the government to supply 6.4 million doses of the Covid-19 vaccine known as Sputnik V developed by the Gamaleya National Research Institute of Epidemiology and Microbiology.

The company has signed a term sheet agreement with the Russian Direct Investment Fund to secure the 6.4 million doses of Sputnik V. Should the definitive supply agreement be successfully executed and the vaccine approved by the Drug Control Authority, the supply of vaccine is expected to contribute positively to the future earnings of the group for the financial year ending Dec 31, 2021.

Tags: theHealth
Previous Post

Vaccine boost

Next Post

Cenergi’s commitment to excellence and diversification

Live Edition Paper

NOV 2020 ePaper

OCT 2020 ePaper


 

Subscribe for free complimentary live editions:

Recent News

  • Painful urination: Early sepsis?
    September 30, 2021
    It is important to detect and treat urinary tract infection early to prevent it […]
  • The amygdala hijack
    December 22, 2022
    Understand how your brain responds to psychological threats such as the […]
  • Another milestone in Duopharma’s digital technology journey
    October 6, 2021
    In a new milestone move to boost Malaysia’s digital health growth, Duopharma […]
  • Tackling the world’s most urgent healthcare needs
    August 16, 2022
    Johnson & Johnson reveals just how far it’s come towards working to help […]
  • Eco-biological clock
    January 1, 2021
    A minimalistic approach to health and lifestyle can do us good In my previous […]

Connect

Office

Revon Media Sdn Bhd
A member of Revongen Corporation
Headquarters
Revongen Corporation Center,
Level 17, Top Glove Tower, No.16,
Persiaran Setia Dagang,Setia Alam,
Seksyen U13, 40170 Shah Alam,
Selangor Darul Ehsan, Malaysia.

Contact

Tel: +603 3359 1166
Fax: +6 03 3358 0303

Copyright © 2021 Revon Media Sdn Bhd. A publication of Revon Media Sdn Bhd. About Us | Contact Us | Privacy Policy | Terms of use

No Result
View All Result
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us

© 2021 Revon Media Sdn Bhd. A publication of Revon Media Sdn Bhd

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist